{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:35:09Z","timestamp":1791477309963,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00467-021-05265-8","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T12:02:53Z","timestamp":1642420973000},"page":"2599-2614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pediatric CKD-MBD: existing and emerging treatment approaches"],"prefix":"10.1007","volume":"37","author":[{"given":"Rose M.","family":"Ayoob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Mahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"5265_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.semnephrol.2012.12.017","volume":"33","author":"K Wesseling-Perry","year":"2013","unstructured":"Wesseling-Perry K, Salusky IB (2013) Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol 33:169\u2013179","journal-title":"Semin Nephrol"},{"key":"5265_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00467-012-2324-4","volume":"28","author":"K Wesseling-Perry","year":"2013","unstructured":"Wesseling-Perry K (2013) Bone disease in pediatric chronic kidney disease. Pediatr Nephrol 28:569\u2013576","journal-title":"Pediatr Nephrol"},{"key":"5265_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11914-017-0365-0","volume":"15","author":"MR Hanudel","year":"2017","unstructured":"Hanudel MR, Salusky IB (2017) Treatment of pediatric chronic kidney disease-mineral and bone disorder. Curr Osteoporos Rep 15:198\u2013206","journal-title":"Curr Osteoporos Rep"},{"key":"5265_CR4","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.2215\/CJN.01330210","volume":"5","author":"SA Bakkaloglu","year":"2010","unstructured":"Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, He-Jing Wang, Elashoff RM, Salusky IB (2010) Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol 5:1860\u20131866","journal-title":"Clin J Am Soc Nephrol"},{"key":"5265_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ki.2010.352","volume":"79","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Blashoff R, Juppner H, Salusky IB (2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79:112\u2013119","journal-title":"Kidney Int"},{"key":"5265_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","volume":"70","author":"T Isakova","year":"2017","unstructured":"Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, Bansal V, Rosas SE, Nigwekar S, Yee J, Kramer H (2017) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 70:737\u2013751","journal-title":"Am J Kidney Dis"},{"key":"5265_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/TP.0000000000000903","volume":"100","author":"ME Seifert","year":"2016","unstructured":"Seifert ME, Hruska KA (2016) The kidney-vascular-bone axis in the chronic kidney disease-mineral bone disorder. Transplantation 100:497\u2013505","journal-title":"Transplantation"},{"key":"5265_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1359\/jbmr.1998.13.8.1213","volume":"13","author":"AM Parfitt","year":"1998","unstructured":"Parfitt AM (1998) A structural approach to renal bone disease. J Bone Miner Res 13:1213\u20131220","journal-title":"J Bone Miner Res"},{"key":"5265_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00467-009-1248-0","volume":"25","author":"LT Weber","year":"2010","unstructured":"Weber LT, Mehls O (2010) Limitations of dual x-ray absorptiometry in children with chronic kidney disease. Pediatr Nephrol 25:3\u20135","journal-title":"Pediatr Nephrol"},{"key":"5265_CR10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.jbiomech.2004.06.007","volume":"38","author":"E Mittra","year":"2005","unstructured":"Mittra E, Rubin C, Qin YX (2005) Interrelationship of trabecular mechanical and microstructural properties in sheep trabecular bone. J Biomech 38:1229\u20131237","journal-title":"J Biomech"},{"key":"5265_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00467-019-04271-1","volume":"35","author":"AD Lalayiannis","year":"2020","unstructured":"Lalayiannis AD, Crabtree NJ, Fewtrell M, Biassoni L, Milford DV, Ferro CJ, Shroff R (2020) Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available? Pediatr Nephrol 35:937\u2013957","journal-title":"Pediatr Nephrol"},{"key":"5265_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1681\/ASN.2015020152","volume":"27","author":"MR Denberg","year":"2016","unstructured":"Denberg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB (2016) Fracture burden and risk factors in childhood CKD: results from the CKiD cohort study. J Am Soc Nephrol 27:543\u2013550","journal-title":"J Am Soc Nephrol"},{"key":"5265_CR13","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1210\/jc.2012-4188","volume":"98","author":"MR Denburg","year":"2013","unstructured":"Denburg MR, Tsampalieros AK, de Boer IH, Shults J, Kalkwarf HJ, Zemel BS, Foerster D, Stokes D, Leonard MB (2013) Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease. J Clin Endo Met 98:1930\u20131938","journal-title":"J Clin Endo Met"},{"key":"5265_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.kint.2016.04.024","volume":"90","author":"NA Dhayat","year":"2016","unstructured":"Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehret G, Guessous I, Leichtle AB, Paccaud F, Mohaupt M, Fiedler GM, Devuyst O, Pech\u00e8re-Bertschi A, Burnier M, Martin PY, Bochud M, Vogt B, Fuster DG (2016) Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int 90:648\u2013657","journal-title":"Kidney Int"},{"key":"5265_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s11914-017-0368-x","volume":"15","author":"KMH Gallant","year":"2017","unstructured":"Gallant KMH, Spiegel DM (2017) Calcium balance in chronic kidney disease. Curr Osteoporos Rep 15:214\u2013221","journal-title":"Curr Osteoporos Rep"},{"key":"5265_CR16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.kint.2018.12.014","volume":"95","author":"P Sanchis","year":"2019","unstructured":"Sanchis P, Ho CY, Liu Y, Beltran LE, Ahmad S, Jacob AP, Furmanik M, Laycock J, Long DA, Shroff R, Shanahan CM (2019) Arterial \u201cinflammaging\u201d drives vascular calcification in children on dialysis. Kidney Int 95:958\u2013972","journal-title":"Kidney Int"},{"key":"5265_CR17","doi-asserted-by":"publisher","first-page":"e13940","DOI":"10.1111\/petr.13940","volume":"25","author":"K Kusumi","year":"2021","unstructured":"Kusumi K, Shaikhkhalil A, Patel H, Mahan JD (2021) Promoting bone health in children and adolescents following solid organ transplantation. Pediatr Transplantation 25:e13940","journal-title":"Pediatr Transplantation"},{"key":"5265_CR18","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney. Int Suppl 113:S1\u2013S130","journal-title":"Int Suppl"},{"key":"5265_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2014a single-center cohort study. Nephrol Dial Transplant 27:345\u2013351","journal-title":"Nephrol Dial Transplant"},{"key":"5265_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2215\/CJN.06040614","volume":"10","author":"KL Naylor","year":"2015","unstructured":"Naylor KL, Garg AX, Zou G, Langsetmo L, Leslie WD, Fraser L-A, Adachi JD, Morin S, Goltzman D, Lentle B, Jackson SA, Josse RG, Jamalet SA (2015) Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 10:646\u2013653","journal-title":"Clin J Am Soc Nephrol"},{"key":"5265_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jocd.2014.01.007","volume":"17","author":"Gordon CM, Leonard MB, Zemel BS; International Society for Clinical Densitometry","year":"2014","unstructured":"Gordon CM, Leonard MB, Zemel BS; International Society for Clinical Densitometry (2014) 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom 17:219\u2013224","journal-title":"J Clin Densitom"},{"key":"5265_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.semnephrol.2003.08.009","volume":"24","author":"IB Salusky","year":"2004","unstructured":"Salusky IB, Kuizon BG, Juppner H (2004) Special aspects of renal osteodystrophy in children. Semin Nephrol 24:69\u201377","journal-title":"Semin Nephrol"},{"key":"5265_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/nep.13017","volume":"22","author":"T Diamond","year":"2017","unstructured":"Diamond T, Elder GJ (2017) Is there a practical role for bone biopsy in chronic kidney disease? Nephrology (Carlton) 22:22\u201326","journal-title":"Nephrology (Carlton)"},{"key":"5265_CR24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/j.1651-2227.2008.00845.x","volume":"97","author":"O Mehls","year":"2008","unstructured":"Mehls O, W\u00fchl E, T\u00f6nshoff B, Schafer F, Nissel R, Haffner D (2008) Growth hormone treatment in short children with chronic kidney disease. Acta Paediatr 97:1159\u20131164","journal-title":"Acta Paediatr"},{"key":"5265_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00467-007-0527-x","volume":"23","author":"S Mahesh","year":"2008","unstructured":"Mahesh S, Kaskel F (2008) Growth hormone axis in chronic kidney disease. Pediatr Nephrol 23:41\u201348","journal-title":"Pediatr Nephrol"},{"key":"5265_CR26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1053\/ajkd.1998.v31.pm9631833","volume":"31","author":"R Hirschberg","year":"1998","unstructured":"Hirschberg R, Adler S (1998) Insulin-like growth factor system and the kidney: physiology, pathophysiology, and therapeutic implications. Am J Kidney Dis 31:901\u2013919","journal-title":"Am J Kidney Dis"},{"key":"5265_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.ackd.2011.02.005","volume":"18","author":"HS Janjua","year":"2011","unstructured":"Janjua HS, Mahan JD (2011) Growth in chronic kidney disease. Adv Chronic Kidney Dis 18:324\u2013331","journal-title":"Adv Chronic Kidney Dis"},{"key":"5265_CR28","first-page":"259","volume-title":"Textbook of Nephro-Endocrinology","author":"JD Mahan","year":"2017","unstructured":"Mahan JD, Ayoob RA (2017) Growth hormone. In: Singh AK, Williams GH (eds) Textbook of Nephro-Endocrinology. Academic Press, San Diego, CA, pp 259\u2013276"},{"key":"5265_CR29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS, Kestenbaum BK (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23:1407\u20131415","journal-title":"J Am Soc Nephrol"},{"key":"5265_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S2352-4642(17)30018-4","volume":"1","author":"L Rees","year":"2017","unstructured":"Rees L, Schafer F, Schmitt CP, Shroff R et al (2017) Chronic dialysis in children and adolescents: challenges and outcomes. Lancet Child Adolesc Health 1:68\u201377","journal-title":"Lancet Child Adolesc Health"},{"key":"5265_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00467-019-04370-z","volume":"35","author":"L McAlister","year":"2020","unstructured":"McAlister L, Pugh P, Greenbaum L, Haffner D, Rees L, Anderson C, Desloovere A, Nelms C, Oosterveld M, Paglialonga F, Polderman N, Qizalbash L, Renken-Terhaerdt J, Tuokkola J, Warady B, Vande Walle J, Shaw V, Shroff R (2020) The dietary management of calcium and phosphate in children with CKD stages 2\u20135 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 35:501\u2013518","journal-title":"Pediatr Nephrol"},{"key":"5265_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00467-007-0684-y","volume":"23","author":"L Rees","year":"2008","unstructured":"Rees L (2008) What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence? Pediatr Nephrol 23:179\u2013184","journal-title":"Pediatr Nephrol"},{"key":"5265_CR33","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2215\/CJN.11031017","volume":"13","author":"P Khairallah","year":"2018","unstructured":"Khairallah P, Nickolas TL (2018) Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13:962\u2013969","journal-title":"Clin J Am Soc Nephrol"},{"key":"5265_CR34","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00467-010-1739-z","volume":"26","author":"D Haffner","year":"2011","unstructured":"Haffner D, Fischer DC (2011) Can bisphosphonates play a role in the treatment of children with chronic kidney disease? Pediatr Nephrol 26:2111\u20132119","journal-title":"Pediatr Nephrol"},{"key":"5265_CR35","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla A (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032\u20131045","journal-title":"Mayo Clin Proc"},{"key":"5265_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"JR Green","year":"2004","unstructured":"Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9:3\u201313","journal-title":"Oncologist"},{"key":"5265_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2215\/CJN.02550508","volume":"4","author":"ND Toussaint","year":"2009","unstructured":"Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221\u2013233","journal-title":"Clin J Am Soc Nephrol"},{"key":"5265_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00223-002-1006-9","volume":"71","author":"PA Price","year":"2002","unstructured":"Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356\u2013363","journal-title":"Calcif Tissue Int"},{"key":"5265_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/01.ATV.21.5.817","volume":"21","author":"PA Price","year":"2001","unstructured":"Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817\u2013824","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5265_CR40","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux PD, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105\u20132115","journal-title":"J Bone Miner Res"},{"key":"5265_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22:503\u2013508","journal-title":"J Bone Miner Res"},{"key":"5265_CR42","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00774-014-0618-2","volume":"33","author":"K Kusumi","year":"2015","unstructured":"Kusumi K, Ayoob R, Bowden SA, Ingraham S, Mahan JD (2015) Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age. J Bone Miner Metab 33:560\u2013566","journal-title":"J Bone Miner Metab"},{"key":"5265_CR43","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1515\/jpem-2014-0525","volume":"29","author":"SA Bowden","year":"2016","unstructured":"Bowden SA, Akusoba CI, Hayes JR, Mahan JD (2016) Biochemical markers of bone turnover in children with clinical bone fragility. J Pediatr Endocrinol Metab 29:715\u2013722","journal-title":"J Pediatr Endocrinol Metab"},{"key":"5265_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s11914-017-0401-0","volume":"15","author":"A Biggin","year":"2017","unstructured":"Biggin A, Munns CF (2017) Long-term bisphosphonate therapy in osteogenesis imperfecta. Curr Osteoporos Rep 15:412\u2013418","journal-title":"Curr Osteoporos Rep"},{"key":"5265_CR45","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/tp.2017.09.10","volume":"6","author":"SA Bowden","year":"2017","unstructured":"Bowden SA, Mahan JD (2017) Zoledronic acid in pediatric metabolic bone disorders. Trans Peds 6:256\u2013256","journal-title":"Trans Peds"},{"key":"5265_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1874325000903010014","volume":"3","author":"JRC Rey","year":"2009","unstructured":"Rey JRC, Cervino EV, Rentero ML, Crespo EC, \u00c1lvaro AO, Casillas M (2009) Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J 3:14\u201321","journal-title":"Open Orthop J"},{"key":"5265_CR47","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/CIA.S120175","volume":"11","author":"A Nishikawa","year":"2016","unstructured":"Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto M, Enomoto H (2016) Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging 11:1653\u20131659","journal-title":"Clin Interv Aging"},{"key":"5265_CR48","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u20132039","journal-title":"N Engl J Med"},{"key":"5265_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1759720X18805759","volume":"10","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM (2018) New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 10:209\u2013223","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5265_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","volume":"15","author":"AM Boyce","year":"2017","unstructured":"Boyce AM (2017) Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 15:283\u2013292","journal-title":"Curr Osteoporos Rep"},{"key":"5265_CR51","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s10067-016-3447-y","volume":"36","author":"B-C Cheng","year":"2017","unstructured":"Cheng B-C, Chen Y-C (2017) Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density. Clin Rheumatol 36:929\u2013932","journal-title":"Clin Rheumatol"},{"key":"5265_CR52","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1053\/j.ajkd.2012.12.010","volume":"61","author":"K Nawrot-Wawrzyniak","year":"2013","unstructured":"Nawrot-Wawrzyniak K, Misof BM, Roscher P, Panczyk-Tomaszewska Zi\u00f3\u0142kowska H, Klaushofer K, Fratzl-Zelman N (2013) Changes in bone matrix mineralization after growth hormone treatment in children and adolescents with chronic kidney failure treated by dialysis: a paired biopsy study. Am J Kidney Dis 61:767\u2013777","journal-title":"Am J Kidney Dis"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05265-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:10:36Z","timestamp":1663679436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05265-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5265"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05265-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"9 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}